Form 4: Moleculin Biotech Executive Donald H. Picker Reports Stock Transactions

Donald H. Picker, Chief Science Officer of Moleculin Biotech, Inc., reports the disposition and acquisition of common stock and restricted stock units on June 22, 2024.

Summary

• On June 22, 2024, Donald H. Picker, the Chief Science Officer of Moleculin Biotech, Inc., engaged in transactions involving the company's stock.
• Picker disposed of 1,766 shares of common stock.
• Picker also disposed of 524 shares for tax purposes related to the vesting of restricted stock units at a price of $3.74.
• Following these transactions, Picker directly owns 8,001 shares of common stock.
• Picker also owns 26,358 restricted stock units.
• The restricted stock units convert into common stock on a one-for-one basis and vest in four equal annual installments beginning on June 22, 2024.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to investors regarding the actions of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The information disclosed is consistent with SEC regulations and reporting requirements.
• Similar filings can be observed across the biotechnology industry for executives at companies like Amgen, Gilead, and Biogen.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in insider ownership.
• The vesting of restricted stock units could have a slight dilutive effect.

Key Dates

Keywords

Moleculin Biotech, MBRX, Donald H. Picker, Chief Science Officer, Form 4, Stock Transaction, Restricted Stock Units, Beneficial Ownership